08:12 AM EDT, 05/15/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) said Friday it secured the European Commission's marketing authorization for insulin lispro biosimilar Bysumlog and insulin aspart biosimilar Dazparda to treat diabetes mellitus in adults, adolescents and children.

The injectable insulins have equivalent efficacy and comparable safety to their reference medicines, Eli Lilly's (LLY.SW, LLY.F) Humalog and Novo Nordisk's (NOVO-B.CO) NovoRapid.

The Swiss drugmaker will commercialize the biosimilar drugs in Europe and other key territories under a 2018 agreement with China's Gan &Lee Pharmaceuticals.

Eli Lilly

Senast

1 013,10

1 dag %

2,53%

1 dag

1 mån

1 år

Sandoz Group AG

Senast

64,80

1 dag %

−1,46%

Novo Nordisk ADR

Senast

44,13

1 dag %

−1,36%

Novo Nordisk B

Senast

286,00

1 dag %

−4,41%
Marknadsöversikt

1 DAG %

Senast

1 mån